TrialThe European respiratory journal2021

A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19.

Dave Singh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.